| Cat.No. | Name | Information |
|---|---|---|
| M8959 | BMS-1 (PD-1/PD-L1 inhibitor 1, PD1-PDL1-IN1) | BMS-1 (PD-1/PD-L1 inhibitor 1, PD1-PDL1-IN1) is an inhibitor of PD-1/PD-L1 protein/protein interaction with an IC50 of 6 to 100 nM. |
| M6101 | Atezolizumab | Atezolizumab (atezolizumab) is a humanized anti-PD-L1 monoclonal antibody that inhibits PD-L1 signaling with PD-1 and B7-1 and restores tumor-specific T-cell immunity. However, it does not affect the interaction of PD-L2 with PD-1. Atezolizumab reacts with murine PD-L1 (for human and non-humanized mice). |
| M3813 | Avelumab (MSB0010718C) | Avelumab is a whole monoclonal antibody of isotype IgG1 that binds to the programmed death-ligand 1 (PD-L1) and therefore inhibits binding to its receptor programmed cell death 1 (PD-1). Avelumab recognizes murine PD-L1 |
| M6100 | Nivolumab | Nivolumab (nabumab) is a fully humanized IgG4 monoclonal antibody against PD-1. It has immune checkpoint inhibitory activity and antitumor activity; MW: 143.597 KD.(for human-derived mice). |
| M5144 | BMS202 | Bms-202 is an effective non-peptide PD-1/PD-L complex inhibitor with IC50 of 18 nM and KD of 8 μM. Bms-202 directly binds to PD-L1 and blocks the human PD-1/PD-L interaction. Bms-202 has antitumor activity. |
| M6102 | Pembrolizumab | Pembrolizumab (pembrolizumab) is a humanized anti-PD-1 monoclonal antibody that blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2. It has immune checkpoint inhibitory activity and antitumor activity. MW: 146.286 KD.(Pembrolizumab does not recognize murine PD-1 protein, humanized mice or mice expressing human PD-1 gene are required). |
| M21116 | ARB-272572 | ARB-272572 is a potent small molecule PD-L1 inhibitor that inhibits the PD-1/PD-L1 axis by inducing cell-surface PD-L1 dimerization via a cis-interacting homodimer with an IC50 value of 400 pM. |
| M20859 | AUNP-12 | AUNP-12, a new immune checkpoint modulator, is an inhibitor of the PD-1 pathway. |
| M15101 | Cemiplimab | Cemiplimab (Libtayo) is a human monoclonal antibody injected intravenously that targets programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands PD-1 and PD-L2. Cemiplimab blocks T-cell inactivation and boosts the immune system's antitumor response. |
| M14104 | CA-170 | CA-170 is an orally delivered dual inhibitor of VISTA and PD-L1. |
| M13464 | Erianin | Erianin, a bibenzyl analog isolated from Dendrobium bulbosum, is also a PD-L1 inhibitor that exhibits potential antitumor activity in a variety of malignant tumors.Erianin regulates a variety of cancer-associated pathways in vitro and in vivo, including apoptosis, cell-cycle arrest, invasion, migration, and autophagy. In addition, Erianin inhibits indoleamine-2,3-dioxygenase (IDO)-induced tumor angiogenesis. |
| M11456 | Evixapodlin | Evixapodlin (PD-1/ PD-L1-in 7) is an inhibitor of human PD-1/PD-L1 protein/protein interaction with an IC50 of 0.213 nM. Evixapodlin has anti-cancer and anti-virus properties. |
| M11421 | AUNP-12 TFA | Aunp-12 (NP-12) TFA is a peptide antagonist of the PD-1 signaling pathway, which has an equivalent antagonistic effect on PD-L1 and PD-L2 in terms of inhibiting lymphocyte proliferation and effector function. Aunp-12 TFA has immune-activating effect and good anti-tumor activity, which has the potential to better study immune-related adverse events (irAEs). |
| M11354 | INCB086550 | INCB086550 selectively inhibited PD-L1 with IC50 of 3.1 nM, 4.9 nM and 1.9 nM for human, rhesus monkey and rat pD-L1, respectively. INCB086550 could not inhibit the binding of PD-L2 to PD-1 at 10 μM. INCB086550 significantly inhibits the PD-1/PD-L1 signaling axis by binding to PD-L1 protein, leading to PD-L1 dimerization and internalization, and has good tumor suppressive effect in a variety of mouse tumor models. |
| M10890 | Spartalizumab | Spartalizumab (anti-PD-1) is a human-derived IgG4 antibody against PD-1 that inhibits the binding of PD-L1 and PD-L2 to PD-1. PDR001 binds to PD-1 with high affinity to inhibit its biological activity; MW: 145.8 KD. |
| M10290 | BMS-1166 | BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor, which binds to human PD-L1 and blocks its interaction with PD-1. |
| M10288 | BMS-1001 | Bms-1001 Hydrochloride is orally active and is an inhibitor of the human PD-L1/PD-1 immune checkpoint. Bms-1001 Hydrochloride is characterized by low cytotoxicity.r. |
| M9416 | Durvalumab | Durvalumab (MEDI 4736) is an humanized anti-PD-L1 monoclonal antibody, it completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively. Durvalumab was inactive against the mPD-L1. |
| M5979 | Sulfamethoxypyridazine | Sulfamethoxypyridazine is a long-acting sulfonamide for treatment of Dermatitis herpetiformis. |
| M4556 | Fraxinellone | Fraxinellone was isolated from the root bark of the brassica family Dictamnus dasycarpus. Fraxinellone is a PD-L1 inhibitor that inhibits HIF-1α synthesis without affecting HIF-1α degradation. Fraxinellone has potential for cancer immunity by targeting PD-L1. |
| M4093 | Panaxadiol | Panaxadiol exists in ginseng root and has neuroprotective and anti-tumor functions. Panaxadiol inhibits the expression of programmed cell death ligand-1 (PD-L1) and tumor proliferation. |
| M58107 | PD-1/PD-L1-IN-9 | PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC50 of 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 also exhibits significant in vivo antitumor activity in a CT26 mouse model. |
| M56388 | NSC622608 | NSC622608 is a V-domain Ig suppressor of T-cell activation (VISTA) ligand with an IC50 value of 4.8 μM. |
| M56387 | PD-L1-IN-1 | PD-L1-IN-1 is a potent PD-L1 inhibitor with an IC50 of 115 nM. |
| M55253 | SL-279252 | SL-279252 (PD1-Fc-OX40L) is a hexameric, bi-functional fusion protein with an ECD of PD-1 (70 pM affinity to PD-L1) linked to the ECD of OX40L (324 pM affinity for OX40) through an Fc linker. SL-279252 exhibited linear PK at doses up to 3.0 mg/kg, and a greater than proportional increase in AUC was observed at 6.0 mg/kg suggesting potential receptor saturation. The preliminary half-life is approximately 23 hours. |
| M55035 | Rosnilimab | Rosnilimab is a novel PD-1 checkpoint agonist antibody that reduces overactive T cell inflammation. Rosnilimab optimizes PD-1+ T cell inhibitory signaling by enabling tight immune synapse formation. Rosnilimab restores immune balance bringing T cell composition to a less activated state. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
